Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Other Non-Current Assets

Last Annual Value

-63.00

3-Year CAGR

98%

5-Year CAGR

88%

10-Year CAGR

%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Other Non-Current Assets

NTRB · NASDAQ
CompanyOther Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
-63.00
N/AN/AN/A 
71.35M
120.3%N/AN/A
19.50K
-23.2%-7.2%-1.2%
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
0.00
N/AN/AN/A
1.86M
40.8%36.8%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
76.00K
-54.8%-48.2%-40.2%
33.70K
-13.4%-8.8%N/A
34.78K
-26.0%-15.1%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
0.00
N/AN/AN/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
12.69M
32.9%39.7%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
0.00
N/AN/AN/A
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15